Why Baxter Acute?

When you choose Baxter for your CRRT program, you’re not only choosing industry-leading technology, you are also selecting a partner dedicated to optimizing your clinical success.

PRISMAFLEX System closeup with Doctor showing Nurse a patient file in background.

Complete Support You Can Count On

We have a multitude of resources to provide you continued support and help you optimize your program. And with over 200 field personnel in the U.S., Baxter always has someone nearby you can depend on.

Comprehensive therapy implementation

24/7 clinical and technical support

Ongoing clinical education

Prismax system in COVID-19 ICU

A Portfolio Designed With Safety and Flexibility in Mind

Because no two AKI patients are the same, our entire product portfolio is designed with your ease of use and safety in mind.

Delivery of multiple CRRT modes, as well as TPE (Therapeutic Plasma Exchange), on the same platform with the PRISMAX and PRISMAFLEX Systems

Simplified electrolyte management with a wide selection of sterile solution formulation options

Proven performance with hemofilter sets designed for easy set-up and maximized therapy delivery

Melissa Thompson-Bastin headshot

Personal Experiences With CRRT

"I just remember he was suffering from a life-threatening arrhythmia, attributed to the potassium levels. And he was too unstable for normal dialysis. Because we had that option (CRRT), we were able to decrease his serum potassium rapidly, without worsening his hypotension, without worsening his other organ failure, and stop the arrhythmogenic situation."

-Melissa Bastin-Thompson, PharmD, BCPS

The PRISMAFLEX and PRISMAX Systems are intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.

Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.

Rx Only. For safe and proper use of products mentioned herein refer to the appropriate Instructions for Use or Operator's Manual.

PHOXILLUM and PRISMASOL Renal Replacement Solution Indications and Important Risk Information

Indications and Usage 
PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Warnings and Precautions 
Electrolyte and Volume Abnormalities
PHOXILLUM and PRISMASOL solutions can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis.

Blood Glucose Abnormalities
The use of PRISMASOL and PHOXILLUM replacement solutions can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

Please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information.

MARS is indicated for the treatment of drug overdose and poisonings. The only requirement is that the drug or chemical be dialyzable (in unbound form) and bound by charcoal and/or ion exchange resins.

MARS is not indicated for the treatment of chronic liver disease conditions or as a bridge to liver transplant. Safety and efficacy has not been demonstrated for those indications in controlled, randomized clinical trials. The effectiveness of the MARS device in patients that are sedated could not be established in clinical studies and therefore cannot be predicted in sedated patients.